Why the study?
Does durable LVAD therapy provide comparable survival outcomes to heart transplantation in adults <50 years of age?
RCT
Yes
Does durable LVAD therapy provide comparable survival outcomes to heart transplantation in adults <50 years of age?
An LVAD-first strategy may be a viable initial approach to heart replacement therapy in appropriately selected adults under 50, offering comparable survival to heart transplantation.
Contemporary data suggest that durable LVAD therapy may offer survival outcomes comparable to HT in adults <50 years of age. These findings support the consideration of an LVAD-first strategy as a viable initial approach to heart replacement therapy in appropriately selected patients. (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 Investigational Device Exemption [MOMENTUM 3 IDE]; NCT02224755) (MOMENTUM 3 Continued Access Protocol [MOMENTUM 3 CAP]; NCT02892955).
No takes yet. Share an insight, caveat, or question.
Uriel et al. (2026) conducted an RCT in Advanced heart failure requiring heart replacement therapy. Durable LVAD therapy (HeartMate 3) vs. Heart transplantation (HT) was evaluated on Survival outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: